BREATHE 5-OL: Tracleer (Bosentan) in Patients With Pulmonary Arterial Hypertension Related to Eisenmenger Physiology
Status:
Completed
Trial end date:
2005-12-01
Target enrollment:
Participant gender:
Summary
This 6-month open label study will evaluate the long term safety of bosentan (via oxygen
saturation) and efficacy (exercise capacity) in patients who have completed the BREATHE-5
study (PAH related to Eisenmenger physiology). Treatment duration is 6 months.